🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 19 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
23/03/2011 10,50 10,98 10,44 10,98 +4,57% 5,14% 129.750
22/03/2011 10,62 10,86 10,50 10,50 -1,13% 3,39% 91.250
21/03/2011 10,80 11,16 10,50 10,62 -1,12% 6,11% 108.217
18/03/2011 10,44 10,74 10,44 10,74 +3,47% 2,87% 101.750
17/03/2011 10,38 10,80 10,32 10,38 +0,58% 4,62% 103.400
16/03/2011 10,62 10,86 10,26 10,32 -3,91% 5,65% 179.283
15/03/2011 10,80 10,86 10,44 10,74 -2,72% 3,89% 314.450
14/03/2011 11,28 11,34 10,92 11,04 -3,16% 3,72% 153.700
11/03/2011 11,10 11,88 10,92 11,40 +1,06% 8,65% 241.383
10/03/2011 11,40 11,64 11,28 11,28 -2,59% 3,16% 158.683
09/03/2011 11,46 11,70 11,40 11,58 +1,58% 2,62% 119.950
08/03/2011 11,40 11,70 11,34 11,40 +0,00% 3,16% 107.767
07/03/2011 11,70 11,94 11,34 11,40 -2,56% 5,13% 121.433
04/03/2011 11,76 12,00 11,46 11,70 +0,00% 4,59% 85.017
03/03/2011 11,82 11,88 11,46 11,70 +0,00% 3,55% 96.700
02/03/2011 11,58 11,88 11,46 11,70 +1,56% 3,63% 123.500
01/03/2011 12,06 12,12 11,52 11,52 -4,00% 4,98% 127.483
28/02/2011 12,24 12,42 11,64 12,00 +0,50% 6,37% 150.750
25/02/2011 11,52 11,94 11,52 11,94 +3,65% 3,65% 286.217
24/02/2011 11,58 11,64 11,40 11,52 +0,00% 2,07% 187.633
23/02/2011 11,70 11,82 11,16 11,52 -2,04% 5,64% 255.550
22/02/2011 12,48 12,48 11,76 11,76 -5,77% 5,77% 228.733
18/02/2011 12,48 13,02 12,42 12,48 +0,97% 4,81% 327.067
17/02/2011 12,48 12,48 12,18 12,36 -0,48% 2,40% 110.817
16/02/2011 12,72 12,72 12,12 12,42 +0,98% 4,72% 189.933
15/02/2011 12,48 12,60 11,82 12,30 -1,44% 6,25% 322.533
14/02/2011 12,54 12,66 12,24 12,48 +0,48% 3,35% 148.767
11/02/2011 12,12 12,96 12,12 12,42 +2,99% 6,93% 252.767
10/02/2011 12,36 12,48 12,06 12,06 -3,83% 3,40% 172.883
09/02/2011 12,60 12,78 12,30 12,54 -0,95% 3,81% 165.917